What should we expect from robotic surgery for second primary oropharyngeal cancer?

Tuan-Jen Fang1,2,3,4, Li-Ang Lee5,6,7, Bing-Shan Huang6,7,8

  • 1Department of Otolaryngology Head and Neck Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan. fang3109@cgmh.org.tw.

Insights

Transoral robotic surgery (TORS) is a feasible treatment for selected second primary oropharyngeal cancer (SPOPC) patients. This approach maximizes functional outcomes while preserving oncologic control, offering a viable alternative for managing this complex condition.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Otolaryngology

Background:

  • Outcomes for second primary oropharyngeal cancer (SPOPC) are influenced by other cancers.
  • Management strategies for SPOPC are limited and inconclusive.
  • Transoral robotic surgery (TORS) is proposed for selected SPOPC cases to balance oncologic and functional results.

Purpose of the Study:

  • To assess the feasibility and outcomes of TORS in managing SPOPC.
  • To evaluate loco-regional control, survival rates, and postoperative function in SPOPC patients treated with TORS.

Main Methods:

  • Retrospective analysis of 15 patients who underwent TORS for SPOPC with curative intent.
  • Data collected from January 2011 to June 2015 at a tertiary referral center in Taiwan.
  • Evaluation of loco-regional status, overall survival (OS), disease-specific survival (DSS), and functional outcomes.

Main Results:

  • TORS was completed in 14 of 15 patients with negative pathologic margins.
  • Two-year OS and DSS rates were 53% and 77%, respectively.
  • SPOPC within 6 months and synchronous esophageal cancer in patients <65 years were associated with poorer outcomes.

Conclusions:

  • TORS is a feasible treatment option for selected SPOPC patients.
  • Metachronous T1-2 SPOPC without esophageal primary shows excellent survival post-TORS.
  • TORS offers functional preservation with minimal destruction, especially for patients with limited life expectancy.

Related Concept Videos